August 26, 2024

Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor

August 19, 2024

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes – Nature.com

August 19, 2024

Multiple Myeloma Research Foundation (MMRF) Announces New Publication on CoMMpass Study in Nature Genetics Defining Distinct Subtypes of Multiple Myeloma and High-Risk Genetic Markers

This MMRF-led collaborative initiative is the largest single sequencing study of multiple myeloma patients to date CoMMpass findings provide an unprecedented, clearer definition of patients at highest risk of rapid disease progression and identification of actionable therapeutic targets Data demonstrate that patients often transition to a high-risk subtype at progression Norwalk, Conn., August 19, 2024 – […]

August 13, 2024

Elranatamab Shows Activity, Safety as Compassionate Use in R/R Multiple Myeloma – OncLive

August 12, 2024

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm – Nature.com